Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

NCT04741074 on ClinicalTrials.gov · last registry update 2024-02-09

Stopped early, having planned 15 participants. The sponsor logged completion for 31 January 2023. Primary outcome, as filed: Kidney Transplant Eligibility. semaglutide is approved in the US, but not for diabetic kidney disease — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: TERMINATED
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Geisinger Clinic
Sponsor type: Other
Enrollment: 15
Started: 2021-07-23
Primary completion: 2023-01-31 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Kidney Transplant Eligibility

Conditions studied

CKD · Diabetic Kidney Disease · Type 2 Diabetes Mellitus in Obese · Obesity · Severe Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.